michelle gayari mms holdings cro clinical research organization leadership in pharma industry international 501(c)(3) charity Together Educating All Children in Hospitals (TEACH)

Many leaders say they value their people, but few may mean it as much as Michelle Gayari, Executive Director, Global Operations at MMS. In this candid conversation, Michelle leans in to the power of her teams and what it’s like being part of a stable, growing organization.

What brought you to MMS in the beginning?

Prior to coming to MMS, I had known and worked with Dr. Uma Sharma for almost 10 years at Parke Davis and Pfizer in Ann Arbor, Michigan. When I heard that she was starting her own data-focused CRO, I reached out to see how I could help. In 2007, I created the clinical programming and statistics departments at MMS, and from there, grew into a role that oversees all technical operational functions of the company. Since we started working together more than 20 years ago, I have always had a great deal of respect for Uma and learned a lot from her over the years.

Why have you stayed with the company for more than 10 years?

It’s the people. The growth that MMS has experienced since day one is truly due to the people in our offices across the world. Adding new services every year, working with an increasing number of clients, and recognizing the achievements of each of our colleagues collectively have been very exciting. MMS is unique in that all five of its executive leaders have been with the company for more than ten years, and I think all of us have similar motivations. Growing organically can take time, but I have enjoyed being part of this process. Being actively involved in the spread from one office to having a global network of offices and teams on four continents has been very gratifying. I have also really enjoyed learning about the backgrounds and experiences of our individual colleagues. For me, no two days are alike. Each day bears its own fruit, from seeing a new colleague develop and grow their career to being part of an important approval that helps meet an unmet medical need.

Tell me about the colleagues that work for you. What are they like?

Every single person on our teams is talented and very motivated. It may seem like a canned response, but it’s not – it’s an absolute fact. We focus a lot on teamwork internally, and have a very wide range of experience levels here. Colleagues with more than 20 years of experience are routinely working alongside recent graduates. I believe that you are never too young or too old to learn. This kind of togetherness allows everyone to grow and learn from each other, tightening the bonds of our colleagues and improving colleague engagement. We have an annual mentorship month that features activities on a daily and weekly basis, but I like to think the mentorship month in reality lasts all 12 months of the year. In turn, we transfer this teamwork and philosophy to the sponsors that we support, ensuring our partnership and full team investment in every project.

What is one of your fondest memories from working at MMS?

It’s hard to think of just one. Every time a challenging project comes in, the process of working with the teams, identifying risks and obstacles, and overcoming these, is highly rewarding. To see a team member receive great feedback from a client and then see how their efforts actually affect a patient’s life in a positive way makes me proud to be part of this company. We’ve been able to not only develop highly talented professionals but we play a critical role in the process of bringing life altering drugs to market. I like to say that “good work rises to the top,” and I am continually reminded of that every day at MMS.

Connect with Michelle Gayari

Suggested For You

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

June 14th, 2024

A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives

June 6th, 2024

Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling

perspectives

May 10th, 2024

Psychedelics in Drug Development and Regulatory Considerations Part I: Benefit-Risk

perspectives

April 29th, 2024

Validation of Clinical Dashboards for Decision Making